Volume 14, Number 6 (Sep/Oct 2023)

Editorial

The Importance of Endpoints in Oncology Clinical Trials

Innovative clinical trials identify appropriate endpoints when seeking to evaluate potential new cancer treatments, better ways of using existing medications, or enhanced supportive care techniques. A recent X (formerly Twitter) post hig...

September 18, 2023

Editorial

Precautions for Patients Taking Tamoxifen or Aromatase Inhibitors

Tamoxifen and aromatase inhibitors are widely prescribed therapies for the treatment of breast cancer. Tamoxifen is a selective estrogen receptor modulator that treats hormone-sensitive breast cancers. Research has demonstrated that tamo...

September 18, 2023

Research and Scholarship

‘My Choices, My Wishes’ Program and Its Effect on Chemotherapy at the End of Life and Advance Care Directive Documentation

This program evaluation project evaluated an early integrated oncology advanced practice provider (APP)-run ACP program entitled “My Choices, My Wishes” (MCMW), including its successes and shortcomings.

September 18, 2023

Research and Scholarship

Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma

In the randomized phase II DREAMM-2 study, single-agent belantamab mafodotin demonstrated deep and durable responses and a manageable safety profile in triple-class refractory relapsed/refractory multiple myeloma (RRMM). We present patie...

September 19, 2023

Review Article

Post-Transplant Cyclophosphamide for the Prevention of Graft-vs.-Host Disease in Allogeneic Hematopoietic Cell Transplantation: A Guide to Management for the Advanced Practitioner

Cyclophosphamide remains a critical component to haploidentical transplant conditioning regimens. Post-transplant cyclophosphamide (PTCy) emerged as an effective component of graft-vs.-host disease (GVHD) prophylaxis in the nonmyeloablat...

September 19, 2023

Review Article

Pancreatic Cancer and the Family Connection: The Role of Advanced Practitioners in Screening and Educating Genetically At-Risk Individuals

Pancreatic cancer is the third leading cause of cancer deaths in the United States. It has a 95% mortality rate within 5 years of the initial diagnosis. Pancreatic ductal adenocarcinoma is the most commonly diagnosed histotype. The avera...

September 20, 2023

Grand Rounds

Surgical Management of Gastrointestinal Stromal Tumors

Gastrointestinal stromal tumors (GISTs) are considered rare, but they are one of the most common malignant mesenchymal tumors within the gastrointestinal tract, affecting 4,000 to 6,000 adults in the United States each year. Because gast...

September 19, 2023

Diagnostic Snapshot

Knowing Your Target: Altered Mental Status From an Unsuspected Source

Daratumumab is a human monoclonal antibody targeting CD38 that is used in the treatment of multiple myeloma. In addition to being a target for cancer-related treatment, CD38 also plays a significant role in the immune response to infecti...

September 19, 2023